These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8447156)

  • 1. Potentially negative effects of AIDS vaccines based on recombinant viruses carrying HIV-1 derived envelope gene. A warning on AIDS vaccine development.
    Veljkovic V; Metlas R
    Vaccine; 1993; 11(3):291-2. PubMed ID: 8447156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies.
    Abacioglu YH; Fouts TR; Laman JD; Claassen E; Pincus SH; Moore JP; Roby CA; Kamin-Lewis R; Lewis GK
    AIDS Res Hum Retroviruses; 1994 Apr; 10(4):371-81. PubMed ID: 8068416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
    [No Abstract]   [Full Text] [Related]  

  • 4. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR; Strick N; Li YY; Jiang S
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
    Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
    J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How antibodies block HIV infection: paths to an AIDS vaccine.
    Putney S
    Trends Biochem Sci; 1992 May; 17(5):191-6. PubMed ID: 1350693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
    Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals?
    Rencher SD; Slobod KS; Dawson DH; Lockey TD; Hurwitz JL
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1131-3. PubMed ID: 8554911
    [No Abstract]   [Full Text] [Related]  

  • 9. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization.
    Gao F; Yue L; Craig S; Thornton CL; Robertson DL; McCutchan FE; Bradac JA; Sharp PM; Hahn BH
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1359-68. PubMed ID: 7888189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein.
    Zaghouani H; Hall B; Shah H; Bona C
    Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein.
    Benjouad A; Mabrouk K; Gluckman JC; Fenouillet E
    FEBS Lett; 1994 Mar; 341(2-3):244-50. PubMed ID: 8137947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
    Bruck C; Thiriart C; Fabry L; Francotte M; Pala P; Van Opstal O; Culp J; Rosenberg M; De Wilde M; Heidt P; Heeney J
    Vaccine; 1994 Sep; 12(12):1141-8. PubMed ID: 7998425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Berman PW; Gregory TJ; Riddle L; Nakamura GR; Champe MA; Porter JP; Wurm FM; Hershberg RD; Cobb EK; Eichberg JW
    Nature; 1990 Jun; 345(6276):622-5. PubMed ID: 2190095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques.
    Abimiku AG; Franchini G; Tartaglia J; Aldrich K; Myagkikh M; Markham PD; Chong P; Klein M; Kieny MP; Paoletti E
    Nat Med; 1995 Apr; 1(4):321-9. PubMed ID: 7585061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.
    Lu S; Wyatt R; Richmond JF; Mustafa F; Wang S; Weng J; Montefiori DC; Sodroski J; Robinson HL
    AIDS Res Hum Retroviruses; 1998 Jan; 14(2):151-5. PubMed ID: 9462925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine.
    Fuller DH; Haynes JR
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1433-41. PubMed ID: 7888198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration.
    Lubeck MD; Natuk RJ; Chengalvala M; Chanda PK; Murthy KK; Murthy S; Mizutani S; Lee SG; Wade MS; Bhat BM
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1443-9. PubMed ID: 7888199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.